Associations with disease identified by genome-wide association studies (GWAS) must be replicated and refined to validate causative variants. In the Wellcome Trust Case Control Consortium (WTCCC) GWAS using 14 500 non-synonymous single nucleotide polymorphisms (nsSNP), rs11062385 (a nsSNP in JARID1A) showed nominal association with ankylosing spondylitis (AS) (P ¼ 0.0006, odds ratio (OR) ¼ 1.26, 95% confidence interval (95% CI) ¼ 1.1-1.4). To replicate and refine the association of JARID1A, rs11062385 was genotyped in 730 further cases and compared with allele frequencies in non-AS disease cohorts typed by WTCCC. We replicated the initial association (P ¼ 0.04, OR ¼ 1.16, 95% CI ¼ 1.01-1.34) and identified a strengthened association with AS in a meta-analysis of this new study combined with the original WTCCC study (P ¼ 0.0001, OR ¼ 1.21, 95% CI ¼ 1.10-1.33). We also genotyped nine further intronic tagging SNPs in JARID1A in 1604 AS cases and 1020 new control samples, but none was associated with AS. JARID1A or a locus in strong linkage disequilibrium with it is a positional candidate for susceptibility to AS.
Introduction
Genome-wide association studies (GWAS) are now the preferred route to identifying disease-associated alleles in complex diseases. Considerable progress has been made in the past 5 years using this strategy; for example, more than 50 disease-associated genetic loci have been identified in type I diabetes (reviewed in (ref. 1)), (http://www.t1dbase.org) and more than 30 in rheumatoid arthritis (reviewed in (ref. 2) ). The first GWAS in ankylosing spondylitis (AS), undertaken by the Wellcome Trust Case Control Consortium (WTCCC), employed a limited gene-targeted approach, using just 14 500 nonsynonymous single nucleotide polymorphism (nsSNPs) in 1000 cases and 1500 controls. 3 Two strong candidate genes (ERAP1 and IL23R) were identified and later replicated. 4, 5 Less strong associations with the functional candidates CARD9 and TRADD have also been subsequently strengthened by replication in independent case sample sets and meta-analysis. 6, 7 Here we report further investigation of the initial association observed with a nsSNP in JARID1A by replication and fine mapping.
JARID1A (jumonji, AT-rich interactive domain 1A), also known as lysine-specific demethylase 5A (KDM5A) and retinoblastoma-binding protein 2 (RBP2 or RBBP2), encodes a lysine-specific histone 3 demethylase. 8 It has the JmjN and JmjC domains, the JmjC domain is predicted to be a metalloenzyme catalytic motif that is required for demethylase activity. Other conserved motifs include an ARID domain involved in binding A/T rich DNA, a single C5HC2 zinc-finger, and three PHD fingers involved in mediating protein-protein interactions and binding methylated-lysine residues. It preferentially demethylates tri-methylated histone 3 lysine 4 (H3K4) but can also demethylate di-methyl H3K4. Trimethylated H3K4 marks transcriptionally active genes, so JARID1A has a role in epigenetic regulation and acts as a repressor of gene transcription. JARID1A associates with several nuclear hormone receptors (NRs), including the androgen receptor, to facilitate NR-mediated gene expression. 9 The protein is widely expressed, especially in immune cells such as CD56 þ NK cells, CD8 þ T cells, dendritic cells and CD34 þ cells. 10 The gene is highly conserved across mammals indicating a likely essential function.
Results and discussion
In the WTCCC/TASC nsSNP GWAS, one SNP in JARID1A, rs11062385, showed an association with AS (P ¼ 0.0006, odds ratio (OR) ¼ 1.26, 95% CI ¼ 1.1-1.4). We used a replication set of 730 AS patients who were either members of the National Ankylosing Spondylitis Society (UK), attendees at the Nuffield Orthopaedic Centre (Oxford, UK) or referrals from rheumatologists in the UK. All patients fulfilled the modified New York criteria for AS 11 and were British Caucasians. The study was approved by the research ethics committee board in the UK (MREC project number 98/5/23). Genotypes were compared with data from 2879 individuals with multiple sclerosis, breast cancer or autoimmune thyroid disease from the WTCCC/TASC GWAS. The association was replicated, P ¼ 0.04, OR ¼ 1.16, 95% CI ¼ 1.01-1.34 using the Cochrane-Armitage test of trend. We then combined the data in a meta-analysis. Using the Mantel-Haenszel test for fixed effects OR, P ¼ 0.0001, OR ¼ 1.21, 95% CI ¼ 1.10-1.33 with no evidence of heterogeneity between studies (Cochran statistic P ¼ 0.41).
We identified nine additional tagging SNPs from HapMap data and genotyped them in 1604 AS cases fulfilling the same criteria as above and 1020 new controls who are healthy British Caucasian blood donors and spouses of patients with osteoarthritis. Of the 1604 AS cases in the tagging SNP study, 77% were also in the original WTCCC study; conversely 76% of the cases in the original WTCCC study and our independent replication sample were also in the 1604 AS cases. A schematic of the overlap is shown in Figure 1a . For rs11062357, additional controls (1427 individuals) were identified from the 1958 BC (deposited by P Deloukas, Wellcome Trust Sanger Institute, Cambridge, UK; http:// www.b58cgene.sgul.ac.uk/ October 2008) and combined with those genotyped in this study. No association was seen between any of these additional SNP and AS. The results are shown in Table 1 and the Forest plots for the meta-analysis for rs11062385 are shown in Figure 2 . (58BC) controls generated by WTCCC/TASC under award 076113. The list of investigators who contributed to the data is available from http://www.wtccc.org.uk.
We then searched the mRNA expression database (mRNA by SNP Browser 1-0-1) 12 to assess the JARID1A-associated SNP for any effect on mRNA expression levels. We found the associated SNP (rs11062385) and those in LD with it (rs482514, rs4980874, rs7315852, rs4980877, rs4980885, rs3759371 and rs6489454) showed a highly significant association with expression levels with probe 215698_at, Po1 Â 10 À8 (Table 2 ). This probe covers 2.356 Kb at the 3 0 end of JARID1A (see Figure 1b) .
Here we report independent replication of the original association of a coding SNP, rs11062385, in JARID1A with susceptibility to AS. Although this association falls short of genome wide significance we believe that this is an important finding because the SNP is strongly correlated with expression of JARID1A. The SNP codes for the replacement of a methionine with a threonine at position 865 in a region of the protein with an undefined function. In this study, the minor allele coding for threonine is protective against AS. There is evidence that epigenetic mechanisms may have a role in autoimmune diseases, such as systemic lupus erythematosus where there is hypo-methylation of regulatory regions of pro-inflammatory genes, such as IL-6 and IL-4 in T cells. 13, 14 Histone hypomethylation and hypoacetylation in CD4 þ cells from systemic lupus erythematosus patients has also been demonstrated. 15 DNA and histone H3K9 methyla- Odds Ratio (95% confidence interval) Figure 2 Odds ratio meta-analysis plot of rs11062385 in JARID1A (fixed effects). Forest plot of meta-analysis of WTCCC nsSNP data and replication data for rs11062385. Analysis was done using the StatsDirect software (http://www.statsdirect.com/). WTCCC is the WTCCC nsSNP study. Oxford AS vs disease controls is our replication study of 730 additional cases compared with non-AS disease controls. Combined is the meta-analysis. n ¼ number of AS cases. tion may also be functionally linked through the binding of HP1, a chromodomain-containing protein that recruits DNA methyltransferases to methylate adjacent CpG islands, with consequent downregulation of gene expression. 16 The association with JARID1A reported here may be the first genetic association of a complex disease, other than cancer, 17 with a variant in a gene critical to epigenetic regulation. It is already known that small molecules, which inhibit DNA methylation (by a variety of mechanisms) can be used to treat myelodysplastic syndrome (5-azacytidine), cardiac arrhythmias (procainamide) and blood pressure (hydralazine). 18 Mutations in lysine and arginine methyl transferases have been documented in various cancers and some might be new targets in the treatment of hormonedependent cancers. Histone demethylases have been linked to tumor formation; JARID1A was originally identified from its interaction with retinoblastomaassociated protein 1, a tumor suppressor protein. 8 Small molecule inhibitors of both histone methyl transferases and demethylases are now being sought. 19 In this way the balance between the activity of methylating and demethylating enzymes can be manipulated to control gene expression with the possibility of tilting expression levels away from a disease phenotype.
